3-(2-噻吩甲酰基)丙酸 | 4653-08-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 中文名称: 3-(2-噻吩甲酰基)丙酸
• 中文别名: 4-羰基-4-(2-噻吩基)丁酸；4-氧-4-(2-噻吩)丁酸；3-(2-噻吩甲基)丙酸
• 英文名称: 4-oxo-4-thiophen-2-yl-butyric acid
• 英文别名: 4-oxo-4-(thiophen-2-yl)butanoic acid；3-(2-thenoyl)propionic acid；4-oxo-(2-thienyl)butanoic acid；4-oxo-4-(2-thienyl)butyric acid；4-(2'-thienyl)-4-oxobutanoic acid；4-oxo-4-thiophen-2-ylbutanoic acid
• CAS: 4653-08-1
• 化学式: C₈H₈O₃S
• mdl: MFCD00022502
• 分子量: 184.216
• InChiKey: ULJMYWHLMLRYSO-UHFFFAOYSA-N

物化性质

• 熔点：
  118-121 °C(lit.)
• 沸点：
  400.5±25.0 °C(Predicted)
• 密度：
  1.334±0.06 g/cm3(Predicted)
• 稳定性/保质期：

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  82.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• TSCA：
  Yes
• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2934999090
• 安全说明：
  S26,S36
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  室温且干燥

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product name : 4-Oxo-4-(2-thienyl)butyric acid

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
According to Regulation (EC) No1272/2008
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
According to European Directive 67/548/EEC as amended.
Irritating to eyes, respiratory system and skin.
Label elements
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Hazard symbol(s)
Xi Irritant
R-phrase(s)
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36 Wear suitable protective clothing.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Formula : C8H8O3S
Molecular Weight : 184,21 g/mol
CAS-No. EC-No. Index-No. Classification Concentration
3-(2-Thenoyl)propionic acid
4653-08-1 225-089-5 - Skin Irrit. 2; Eye Irrit. 2; STOT -
SE 3; H315, H319, H335
Xi, R36/37/38
For the full text of the H-Statements mentioned in this Section, see Section 16.

---

Section 4. FIRST AID MEASURES
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing give artificial respiration Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

---

Section 5. FIRE-FIGHTING MEASURES
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for fire-fighters
Wear self contained breathing apparatus for fire fighting if necessary.

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions
Use personal protective equipment. Avoid dust formation. Avoid breathing dust. Ensure adequate ventilation.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Keep in suitable, closed containers for disposal.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire
protection.
Conditions for safe storage
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Personal protective equipment
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a dust mask type N95 (US) or
type P1 (EN 143) respirator. Use respirators and components tested and approved under appropriate
government standards such as NIOSH (US) or CEN (EU).
Hand protection
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the
standard EN 374 derived from it.
Handle with gloves.
Eye protection
Safety glasses with side-shields conforming to EN166
Skin and body protection
Choose body protection according to the amount and concentration of the dangerous substance at the
work place.
Hygiene measures
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at
the end of workday.

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Form solid
Safety data
pH no data available
Melting point 118 - 121 °C - lit.
Boiling point no data available
Flash point no data available
Ignition temperature no data available
Lower explosion limit no data available
Upper explosion limit no data available
Water solubility no data available

---

Section 10. STABILITY AND REACTIVITY
Chemical stability
Stable under recommended storage conditions.
Conditions to avoid
no data available
Materials to avoid
Strong oxidizing agents
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sulphur oxides

---

Section 11. TOXICOLOGICAL INFORMATION
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Additional Information
RTECS: no data available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Product
Observe all federal, state, and local environmental regulations. Contact a licensed professional waste
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn
in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
ADR/RID
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.

---

Section 16. OTHER INFORMATION
Text of H-code(s) and R-phrase(s) mentioned in Section 3
Eye Irrit. Eye irritation
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Skin Irrit. Skin irritation
STOT SE Specific target organ toxicity - single exposure
Xi Irritant
R36/37/38 Irritating to eyes, respiratory system and skin.
Further information
Copyright 2010 Co. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used
only as a guide. The information in this document is based on the present state of our knowledge and is
applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee
of the properties of the product. Co., shall not be held liable for any damage resulting from
handling or from contact with the above product. See reverse side of invoice or packing slip for additional
terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  3-(2-噻吩甲酰基)丙酸 在 劳森试剂 作用下， 以 甲苯 为溶剂， 反应 8.0h， 以13%的产率得到2,2'-联二噻吩
  参考文献：
  名称：

  Ein einfaches Verfahren zur Herstellung anellierter Thiophene

  摘要：

  DOI：

  10.1007/bf00817900
• 作为产物：
  描述：

  4-(噻吩-2-基)丁-3-炔-1-醇 在 重铬酸吡啶 、 三氟甲磺酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 3-(2-噻吩甲酰基)丙酸
  参考文献：
  名称：

  在水中通过Pd / C介导的Sonogashira偶联轻松合成取代的噻吩。

  摘要：

  此处描述了碘噻吩与末端炔烃在水中首次成功的Pd / C介导的Sonogashira偶联。发现Pd / C-CuI-PPh（3）是该偶联反应的有效催化剂体系。使用这种经济可靠的方法，可以以高收率制备各种具有广泛官能团的炔属噻吩。描述了某些合成化合物的合成应用和体外抗癌性能。

  DOI：

  10.1016/j.bmcl.2006.09.041

文献信息

• A Facile Direct Route to <i>N</i> ‐(Un)substituted Lactams by Cycloamination of Oxocarboxylic Acids without External Hydrogen
  作者：Hu Li、Hongguo Wu、Heng Zhang、Yaqiong Su、Song Yang、Emiel J. M. Hensen

  DOI：10.1002/cssc.201901780

  日期：2019.8.22

  Lactams are privileged in bioactive natural products and pharmaceutical agents and widely featured in functional materials. This study presents a novel versatile approach to the direct synthesis of lactams from oxocarboxylic acids without catalyst or external hydrogen. The method involves the in situ release of formic acid from formamides induced by water to facilitate efficient cycloamination. Water

  内酰胺在生物活性天然产物和药物制剂中享有特权，并在功能材料中得到广泛应用。这项研究提出了一种新颖的通用方法，无需催化剂或外部氢就可从含氧羧酸直接合成内酰胺。该方法涉及从水诱导的甲酰胺中原位释放甲酸，以促进有效的环胺化。水还抑制副产物的形成。通过模型实验和密度泛函理论计算的结合阐明了这种非常规途径，其中发现环状亚胺（5-甲基-3,4-二氢-2-吡咯烷酮及其互变异构结构）是形成内酰胺的有利中间体。与包括级联还原胺化和环化的常规方法形成对比。N-未取代和N-取代的内酰胺。
• Synthesis of Reversed <i>C</i> ‐Acyl Glycosides through Ni/Photoredox Dual Catalysis
  作者：Shorouk O. Badir、Audrey Dumoulin、Jennifer K. Matsui、Gary A. Molander

  DOI：10.1002/anie.201800701

  日期：2018.5.28

  incorporation of C‐glycosides in drug design has become a routine practice for medicinal chemists. These naturally occurring building blocks exhibit attractive pharmaceutical profiles, and have become an important target of synthetic efforts in recent decades.1 Described herein is a practical, scalable, and versatile route for the synthesis of non‐anomeric and unexploited C‐acyl glycosides through a Ni/photoredox

  在药物设计中加入C-糖苷已成为药物化学家的常规做法。这些天然存在的结构单元表现出有吸引力的药物特性，并已成为近几十年来合成工作的重要目标。1本文描述的是一种通过 Ni/光氧化还原双催化系统合成非异头和未开发的C-酰基糖苷的实用、可扩展且通用的路线。通过利用有机光催化剂，可以产生一系列糖基自由基，并在室温下与高度功能化的羧酸有效偶联。这种转化的显着特征包括其温和的条件、与多种官能团的令人印象深刻的相容性，以及最重要的是，保留了异头碳：为进一步的后期衍生化提供了手段。
• 一种无催化剂合成内酰胺衍生物的方法
  申请人：贵州大学

  公开号：CN109942473B

  公开（公告）日：2020-09-15

  本发明公开了一种内酰胺衍生物的简易合成方法，包括：以甲酰胺为胺源和氢供体(水解产生甲酸)，酮酸为原料，在无溶剂和催化剂的条件下，经成环胺化反应简易合成内酰胺衍生物。与先前报道相比，本反应所需时间大大缩短、选择性得到显著提高，酮酸类衍生物的转化率>99％，内酰胺衍生物产率可达到70～94％。
• .omega.-Heteroaroyl(propionyl or butyryl)-L-prolines
  申请人：American Cyanamid Company

  公开号：US04299769A1

  公开（公告）日：1981-11-10

  This disclosure describes novel substituted .omega.-heteroaroyl(propionyl or butyryl)-L-prolines and the esters and cationic salts thereof which are useful as hypotensive agents in mammals.

  这份披露描述了新颖的取代的.omega.-杂芳酰(丙酰或丁酰)-L-脯氨酸及其酯和阳离子盐，它们在哺乳动物中作为降压剂是有用的。
• [EN] OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPERATION AND THEIR USE AS ANTIMYCOBACTERIAL AGENTS<br/>[FR] DERIVES D'OXAZOLIDINONE, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION COMME AGENTS ANTIMYCOBACTERIENTS
  申请人：LUPIN LTD

  公开号：WO2004026848A1

  公开（公告）日：2004-04-01

  Novel compounds belonging to the class of oxazolidinones possessing potent antimycobacterial properties especially useful in the treatment of acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium-intracellular complex, M. fortuitum and M. kansai. The compound and its pharmaceutically acceptable salts thereof act as antibacterial agents. Also disclosed is a method for inhibiting growth of mycobacterial cells a well as a method of treating mycobacterial conditions such as Mycobacterium tuberculoses, drug resistant Mycobacterium tuberculosis, Mycobacterium avium-intracellular complex, M. fortuitum and M. kansai, comprising administering an antimycobacterially effective amount of the said compound and/or pharmaceutically acceptable salts thereof. There is also disclosed a process for the manufacture of the said compound or its pharmaceutically acceptable salts.

  新型化合物属于噁唑烷酮类，具有强效抗分枝杆菌特性，特别适用于治疗酸快速生长的微生物，如结核分枝杆菌、分枝杆菌内复合体、堪萨斯分枝杆菌和康萨分枝杆菌。该化合物及其药学上可接受的盐作为抗菌剂。还公开了一种抑制分枝杆菌细胞生长的方法，以及治疗结核分枝杆菌病、耐药性结核分枝杆菌、分枝杆菌内复合体、堪萨斯分枝杆菌和康萨分枝杆菌等分枝杆菌疾病的方法，包括给予所述化合物和/或其药学上可接受的盐的抗分枝杆菌有效量。还公开了一种制造所述化合物或其药学上可接受的盐的方法。